Tislelizumab (BGB-A317) for Relapsed/Refractory Classical Hodgkin Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study

Conclusions: In this study, tislelizumab therapy was shown to be highly active resulting in a high CR rate in patients with R/R cHL who had failed or were ineligible for ASCT. Tislelizumab was generally well-tolerated in Chinese patients with R/R cHL. The safety profile was generally consistent with that of other PD-1 inhibitors for the treatment of cHL.DisclosuresSong: Peking University Cancer Hospital (Beijing Cancer Hospital): Employment. Liu: West China Hospital of Sichuan University: Employment. Guo: BeiGene (Shanghai) Co., LTD: Employment. Yang: BeiGene (Beijing) Co., Ltd.: Employment. Elstrom: BeiGene (Beijing) Co., Ltd.: Employment, Equity Ownership. Huang: BeiGene (Beijing) Co., Ltd.: Employment, Equity Ownership. Novotny: BeiGene (Beijing) Co., Ltd.: Employment, Equity Ownership. Wei: BeiGene (Beijing) Co., Ltd.: Employment, Equity Ownership. Zhu: Beijing Cancer Hospital: Employment.

Source: Blood - November 21, 2018 Category: Hematology Authors: Song, Y., Gao, Q., Zhang, H., Fan, L., Zhou, J., Zou, D., Li, W., Yang, H., Liu, T., Wang, Q., Lv, F., Yang, Y., Guo, H., Yang, L., Elstrom, R., Huang, J., Novotny, W., Wei, V., Zhu, J. Tags: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies: Immunotherapy and Targeted Strategies Source Type: research